STOCK TITAN

Cosmos Health Inc - COSM STOCK NEWS

Welcome to our dedicated news page for Cosmos Health (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cosmos Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cosmos Health's position in the market.

Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) expects significant revenue growth from recent acquisitions, projecting a $12.5M increase in FY 2024 group revenue, with a gross profit of at least $3.1M and EBITDA in excess of $1.3M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.07%
Tags
-
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) announced the acquisition of the license and rights for 'DIABIT-IS X', a generic drug used in the treatment of type-2 diabetes. The drug is set to be launched in Europe following the expiration of the patent for the branded drug 'Januvia'. Cosmos Health aims to capture a significant share of the European market and generate substantial profits from this investment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.33%
Tags
-
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) CEO Greg Siokas plans to purchase up to $3 million in common shares through open market transactions, with $1 million already purchased in 2023. Siokas believes the shares are undervalued and intends to increase his stake by approximately 20% of the market capitalization. He has invested over $15 million in the company since inception and sees this as a strategic investment given the innovative R&D projects, AI-drug repurposing, planned spinoff of the R&D department, and international brand growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.49%
Tags
none
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) CEO to participate in Invest in Greece Forum, discussing investment opportunities in the healthcare sector. Registration and 1-on-1 meetings available for institutional investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.89%
Tags
conferences
-
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) announced an agreement with Cloudpharm PC to acquire the rights to repurpose a drug for treating various diseases, including CNS cancers and autoimmune diseases. The global brain tumor treatment market is expected to reach $3.1 billion by 2023, with a projected CAGR of 7.2% until 2033. Cosmos Health aims to explore drug repurposing opportunities using advanced technology to deliver medicines faster and more efficiently, targeting major health disorders like cancer, diabetes, and obesity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.76%
Tags
-
Rhea-AI Summary
Cosmos Health Inc. (NASDAQ:COSM) filed a patent application with the European Patent Office for its CCX0722 obesity and weight management product, showcasing significant advancements and promising results in its R&D pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.65%
Tags
none
Rhea-AI Summary
Cosmos Health Inc. (COSM) reported Q3 2023 revenues of $12.8M, a 7% increase YoY, with a solid balance sheet, but decreased gross margins and negative Adjusted EBITDA. The company also announced a strategic collaboration, a capital raise, and guidance to surpass $180M in gross annual revenue and $20M in EBITDA by 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.36%
Tags
-
Rhea-AI Summary
Cosmos Health Inc. announces acquisition of Cloudscreen®, an AI-powered platform for drug repurposing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.71%
Tags
-
Rhea-AI Summary
Cosmos Health Inc. announces major strategic inflection point and strong financial position
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
none
Rhea-AI Summary
Cosmos Health Inc. plans to spin off its R&D division into a standalone biotech company, aiming to unlock shareholder value. The company has been investing in innovative R&D projects, including the CCX0722 product for obesity and weight management. Clinical trials for the product are scheduled to begin in Q4 2023. The spin-off decision is based on analysis of comparable biotech companies. Cosmos Health is also executing a buyback program to return capital to shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.16%
Tags
none
Cosmos Health Inc

Nasdaq:COSM

COSM Rankings

COSM Stock Data

11.88M
10.69M
13.05%
11.61%
3.25%
Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
Wholesale Trade
Link
United States
Chicago